By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioTime today said that it has reached an agreement with the California Institute for Regenerative Medicine to make five clinical-grade human embryonic stem cell lines available to California researchers.

Under terms of the agreement, BioTime will first provide research-grade cell lines. The Alameda, Calif.-based firm also plans within one year to provide GMP-grade cell lines along with certain documentation and complete DNA sequence information.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.